PMID- 34979750
OWN - NLM
STAT- MEDLINE
DCOM- 20220105
LR  - 20220105
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 51
IP  - 1
DP  - 2022 Jan 8
TI  - [Anaplastic lymphoma kinase-translocation renal cell carcinoma: clinical and 
      pathological analysis].
PG  - 28-32
LID - 10.3760/cma.j.cn112151-20210323-00227 [doi]
AB  - Objective: To investigate the clinicopathological features, molecular 
      characteristics, differential diagnosis and prognosis of anaplastic lymphoma 
      kinase (ALK)-translocation renal cell carcinoma. Methods: Two cases of 
      ALK-translocation renal cell carcinoma diagnosed from January 2011 to December 
      2020 were retrospectively analyzed to characterize their morphological features, 
      immunohistochemical expression and prognosis. Multiple molecular studies 
      including fluorescence in situ hybridization (FISH), reverse 
      transcriptase-polymerase chain reaction (RT-PCR), and next-generation sequencing 
      were performed to characterize the genetic alterations. Results: Two patients 
      included one male and one female, with 59 and 57 years old, respectively. 
      Morphologically, case 1 resembled collecting duct carcinoma or renal medullary 
      carcinoma, which demonstrated tubular, microcapsule and reticular structures, 
      with a remarkable myxoid background and lymphocytes infiltration; case 2 
      resembled Xp11.2 translocation renal cell carcinoma or type 2 papillary renal 
      cell carcinoma, which demonstrated tubular papillary and focal solid structures, 
      with flocculent cytoplasm and many foamy histiocytes, but without myxoid 
      background and lymphocytes infiltration. Immunohistochemistry showed strongly 
      positive expression of ALK. CK7, E-cadherin, vimentin, PAX8 and CD10 showed 
      various degrees of expression, and other antibodies were nonreactive. A variety 
      of molecular assays showed definite ALK gene translocation, with rare VCL-ALK 
      gene fusion (VCL exon and 16-ALK exon 20) in case 1, and EML4-ALK gene fusion 
      (EML4 exon and 2-ALK exon 20) in case 2. Conclusions: ALK-translocation renal 
      cell carcinoma is rare with various morphological features, and is easy to miss 
      and misdiagnose. The characteristic ALK expression and molecular detection of ALK 
      translocation are helpful for diagnosing this type of renal cell carcinoma.
FAU - Di, S H
AU  - Di SH
AD  - Department of Pathology, Nanjing Jinling Hospital, Nanjing University School of 
      Medicine, Nanjing 210002, China.
FAU - Wang, X T
AU  - Wang XT
AD  - Department of Pathology, Nanjing Jinling Hospital, Nanjing University School of 
      Medicine, Nanjing 210002, China.
FAU - Xia, Q Y
AU  - Xia QY
AD  - Department of Pathology, Nanjing Jinling Hospital, Nanjing University School of 
      Medicine, Nanjing 210002, China.
FAU - Lu, Z F
AU  - Lu ZF
AD  - Department of Pathology, Nanjing Jinling Hospital, Nanjing University School of 
      Medicine, Nanjing 210002, China.
FAU - Ma, H H
AU  - Ma HH
AD  - Department of Pathology, Nanjing Jinling Hospital, Nanjing University School of 
      Medicine, Nanjing 210002, China.
FAU - Zhang, R S
AU  - Zhang RS
AD  - Department of Pathology, Nanjing Jinling Hospital, Nanjing University School of 
      Medicine, Nanjing 210002, China.
FAU - Wang, X
AU  - Wang X
AD  - Department of Pathology, Nanjing Jinling Hospital, Nanjing University School of 
      Medicine, Nanjing 210002, China.
FAU - Rao, Q
AU  - Rao Q
AD  - Department of Pathology, Nanjing Jinling Hospital, Nanjing University School of 
      Medicine, Nanjing 210002, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - 0 (Oncogene Proteins, Fusion)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
SB  - IM
MH  - Anaplastic Lymphoma Kinase/genetics
MH  - *Carcinoma, Renal Cell/genetics
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Kidney Neoplasms/genetics
MH  - *Lung Neoplasms
MH  - Male
MH  - Oncogene Proteins, Fusion/genetics
MH  - Retrospective Studies
EDAT- 2022/01/05 06:00
MHDA- 2022/01/06 06:00
CRDT- 2022/01/04 02:04
PHST- 2022/01/04 02:04 [entrez]
PHST- 2022/01/05 06:00 [pubmed]
PHST- 2022/01/06 06:00 [medline]
AID - 10.3760/cma.j.cn112151-20210323-00227 [doi]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2022 Jan 8;51(1):28-32. doi: 
      10.3760/cma.j.cn112151-20210323-00227.